Q04206 (TF65_HUMAN) Homo sapiens (Human)

Transcription factor p65 UniProtKBInterProSTRINGInteractive Modelling

551 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4); 1 identical sequence: Gorilla gorilla gorilla: G3SHV6

Available Structures

88 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX
1nfi
 Heteromer
P19838; P25963; 		20-314
Assess
Crystal Structure of NFkB, IRF7, IRF3 bound to the interferon-b enhancer
2o61
 Heteromer
P19838; Q14653; Q92985; 		20-291
Assess
Crystal structure of a higher-order complex of p50:RelA bound to the HIV-1 LTR
3gut
 Heteromer
P19838; 		20-291
Assess
NMR structure of the complex between the KIX domain of CBP and the transactivation domain 1 of p65
5u4k
 Heteromer
P45481; 		521-551
Assess
NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the transacti…
5urn
 Heteromer
P32776; 		521-551
Assess
Structure of importin a3 bound to the p50- and p65-NLSs
7lf4
 Heteromer
O00629; P19838; 		299-311
Assess
solution structures of BRD4 second bromodomain with NF-kB-K310ac peptide
2lsp
 Heteromer
O60885; 		304-316
Assess
14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005
6nv2
 Heteromer
P31947; 		42-50
2×CL; 2×0V4;
Assess
14-3-3 sigma with RelA/p65 binding site pS45
6qhl
 Heteromer
P31947; 		43-51
4×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192
7o59
 Heteromer
P31947; 		43-51
2×V2N; 2×V2K; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046
7o3a
 Heteromer
P31947; 		43-51
4×CL; 2×V0T; 2×CA; 2×GOL; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187
7biw
 Heteromer
P31947; 		43-51
2×TW8; 4×CA; 2×CL; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180
7biq
 Heteromer
P31947; 		43-51
2×TVB; 6×CA; 4×CL; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185
7nws
 Heteromer
P31947; 		43-51
2×UT8; 4×CL; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184
7nxs
 Heteromer
P31947; 		43-51
2×UVK; 2×CL; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183
7nxt
 Heteromer
P31947; 		43-51
2×UVE; 4×CL; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188
7nv4
 Heteromer
P31947; 		43-51
2×UST; 4×CL; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179
7bi3
 Heteromer
P31947; 		43-51
2×TQW; 2×GOL; 4×CA; 2×CL; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181
7nxy
 Heteromer
P31947; 		43-51
2×UVQ; 4×CL; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186
7nvi
 Heteromer
P31947; 		43-51
2×USW; 4×CL; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182
7nxw
 Heteromer
P31947; 		43-51
2×UVZ; 4×CL; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521
6yow
 Heteromer
P31947; 		43-51
2×L3Y;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009
7nqp
 Heteromer
P31947; 		43-51
2×TJ8; 2×MG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142
7bjl
 Heteromer
P31947; 		43-51
2×TWQ;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123
6ypy
 Heteromer
P31947; 		43-51
2×P7E;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120
7nzv
 Heteromer
P31947; 		43-51
2×UXN; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134
7nye
 Heteromer
P31947; 		43-51
2×UVH; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083
7o6j
 Heteromer
P31947; 		43-51
6×V48; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070
7nmh
 Heteromer
P31947; 		43-51
2×GOL; 2×CA; 2×UHZ; 2×CL; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153
7bkh
 Heteromer
P31947; 		43-51
4×U1B;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154
7bjw
 Heteromer
P31947; 		43-51
2×TZW;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157
7o57
 Heteromer
P31947; 		43-51
2×V2E;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124
7nk5
 Heteromer
P31947; 		43-51
2×UGN; 2×CA; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096
7o6o
 Heteromer
P31947; 		43-51
2×V3Z; 2×CL; 2×CA;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069
7bjf
 Heteromer
P31947; 		43-51
2×CL; 2×TZH;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130
7ny4
 Heteromer
P31947; 		43-51
2×UVN; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111
7nr7
 Heteromer
P31947; 		43-51
2×UON; 2×UOT; 2×PEG; 2×CL; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117
7o3f
 Heteromer
P31947; 		43-51
2×V0W; 2×CL; 2×MG; 6×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097
7o6m
 Heteromer
P31947; 		43-51
2×V42; 2×CA; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121
7nzk
 Heteromer
P31947; 		43-51
2×UWK;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132
7njb
 Heteromer
P31947; 		43-51
2×GOL; 2×CL; 2×UG8;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080
7o6k
 Heteromer
P31947; 		43-51
2×V4N; 2×CL; 2×CA; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131
7nyf
 Heteromer
P31947; 		43-51
2×UVB; 2×MG; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125
7nz6
 Heteromer
P31947; 		43-51
2×UWH; 2×CA; 2×CL; 4×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126
7nm1
 Heteromer
P31947; 		43-51
2×UHN; 2×CA; 2×CL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135
7nm3
 Heteromer
P31947; 		43-51
2×UHQ; 4×GOL; 2×CA;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133
7nj9
 Heteromer
P31947; 		43-51
2×UGE; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127
7nyg
 Heteromer
P31947; 		43-51
2×UVT; 2×CL; 2×MG; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122
7nzg
 Heteromer
P31947; 		43-51
2×UWQ; 2×CA;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116
7o3p
 Heteromer
P31947; 		43-51
4×CL; 2×CA; 2×GOL; 2×PEG; 2×V1K;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175
7biy
 Heteromer
P31947; 		43-51
2×CL; 2×TWE;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173
7o5x
 Heteromer
P31947; 		43-51
4×CL; 2×V3W; 2×CA; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159
7o5c
 Heteromer
P31947; 		43-51
2×CL; 2×V2T; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085
7o6i
 Heteromer
P31947; 		43-51
4×CL; 2×V4B; 2×CA;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025
6yoy
 Heteromer
P31947; 		43-51
2×CL; 2×L3S;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011
6yp2
 Heteromer
P31947; 		43-51
2×CL; 2×P5N;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037
6ypl
 Heteromer
P31947; 		43-51
2×CL; 2×P6H;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168
7o5u
 Heteromer
P31947; 		43-51
4×CL; 2×V3T; 2×CA;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158
7o5a
 Heteromer
P31947; 		43-51
2×CL; 2×V2Q;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033
6yp8
 Heteromer
P31947; 		43-51
2×CL; 2×P6Z;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165
7o5o
 Heteromer
P31947; 		43-51
4×CL; 2×V3K; 2×GOL; 2×CA;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161
7o5f
 Heteromer
P31947; 		43-51
4×CL; 2×V32; 2×MG; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176
7o6g
 Heteromer
P31947; 		43-51
4×CL; 2×V4H; 2×CA; 2×PEG; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164
7o5g
 Heteromer
P31947; 		43-51
4×CL; 2×V3B; 4×PEG; 2×MG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041
7o3q
 Heteromer
P31947; 		43-51
6×CL; 2×V1Q; 2×PEG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042
7o3r
 Heteromer
P31947; 		43-51
4×CL; 2×V1E; 2×CA; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044
7bjb
 Heteromer
P31947; 		43-51
2×CL; 2×TZK; 2×GOL; 4×CA; 2×MG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028
6yp3
 Heteromer
P31947; 		43-51
2×CL; 2×P5Q;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166
7o5p
 Heteromer
P31947; 		43-51
2×CL; 2×V3N;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027
6yox
 Heteromer
P31947; 		43-51
2×CL; 2×L3V; 2×CA; 2×MG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043
7o34
 Heteromer
P31947; 		44-51
2×V0Q; 2×MG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129
6yq2
 Heteromer
P31947; 		43-50
2×P7T;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118
7nle
 Heteromer
P31947; 		44-51
2×CL; 2×GOL; 2×UHW;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128
7nk3
 Heteromer
P31947; 		43-50
2×UGQ; 2×CL; 2×CA; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167
7o5s
 Heteromer
P31947; 		43-50
4×CL; 2×V3Q; 2×MG; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045
7o3s
 Heteromer
P31947; 		44-51
4×CL; 2×V1H; 2×MG;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178
7o6f
 Heteromer
P31947; 		43-50
4×CL; 2×V4K; 2×CA; 2×GOL;
Assess
Structure of importin a2 bound to p65-NLS
7leu
 Heteromer
P52293; 		299-306
Assess
14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046
7nsv
 Heteromer
P31947; 		43-49
2×UQN; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119
7nla
 Heteromer
P31947; 		43-49
2×CL; 2×CA; 2×UHT;
Assess
Crystal Structure of Brd4 Bromodomain 1 in Complex with Acetylated Rel Peptide
4kv1
 Heteromer
O60885; 		308-314
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160
7o5d
 Heteromer
P31947; 		43-49
4×CL; 2×V2W; 2×MG; 2×GOL;
Assess
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110
7nm9
 Heteromer
P31947; 		43-48
2×S9E; 2×PEG;
Assess
Human SETD6 in complex with RelA Lys310 peptide
3rc0
 Heteromer
Q8TBK2; 		307-312
10×EDO; 1×SAM;
Assess
Structure of importin a2 bound to the p50- and p65-NLSs
7let
 Heteromer
P19838; P52293; 		299-304
Assess
Brd4 Bromodomain 2 in Complex with Acetylated Rel Peptide
4kv4
 Heteromer
O60885; 		308-312
1×DTT;
Assess
14-3-3 sigma with RelA/p65 binding site pS281
6qhm
 Heteromer
P31947; 		280-282
Assess
Human SETD6 in complex with RelA Lys310
3qxy
 Heteromer
Q8TBK2; 		310-310
1×SAM; 11×EDO;
Assess

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2o61.1.Cmonomer0.8320-291
96.45
Assess
1nfi.1.Amonomer0.7720-313
99.67
Assess
1ooa.1.Bmonomer0.7618-291
44.60
Assess
2lww.1.Bmonomer0.52427-491
81.54
Assess

11 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 22o61.1.Cmonomer0.837-278
94.68
Assess
Isoform 21ooa.1.Bmonomer0.776-278
44.76
Assess
Isoform 21nfi.1.Amonomer0.767-300
98.00
Assess
Isoform 22lww.1.Bmonomer0.52414-478
81.54
Assess
Isoform 32o61.1.Cmonomer0.8020-281
96.32
Assess
Isoform 31nfi.1.Amonomer0.7420-303
99.66
Assess
Isoform 31ooa.1.Bmonomer0.7418-281
45.85
Assess
Isoform 32lww.1.Bmonomer0.51417-481
81.54
Assess
Isoform 42o61.1.Cmonomer0.7920-288
95.70
Assess
Isoform 41nfi.1.Amonomer0.7520-310
98.99
Assess
Isoform 42lww.1.Bmonomer0.52424-488
81.54
Assess